Search Results - "KEPPLER, K. B"

Recent Developments in the Field of Tumor-Inhibiting Metal Complexes by Galanski, M S, Arion, V B, Jakupec, M A, Keppler, B K

“…25 years after the first approval of cisplatin in the clinic against a number of cancer diseases, cisplatin and related compounds continue to be among the most…”
Get more information

Multi-scale imaging of anticancer platinum() compounds in murine tumor and kidney by Legin, A. A, Theiner, S, Schintlmeister, A, Reipert, S, Heffeter, P, Jakupec, M. A, Mayr, J, Varbanov, H. P, Kowol, C. R, Galanski, M. S, Berger, W, Wagner, M, Keppler, B. K

“…Nano-scale secondary ion mass spectrometry (NanoSIMS) enables trace element and isotope analyses with high spatial resolution. This unique capability has…”
Get full text

Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells by KAPITZA, S, PONGRATZ, M, JAKUPEC, M. A, HEFFETER, P, BERGER, W, LACKINGER, L, KEPPLER, B. K, MARIAN, B

“…The ruthenium complex salt indazolium trans-[tetrachlorobisindazole-ruthenate(III)] (KP1019) and the analogous sodium salt KP1339 are effective…”
Get full text

Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24) by Heffeter, P., Jakupec, M.A., Körner, W., Chiba, P., Pirker, C., Dornetshuber, R., Elbling, L., Sutterlüty, H., Micksche, M., Keppler, B.K., Berger, W.

“…Recently, we have introduced [tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772, FFC24) as a new lanthanum compound which has promising anticancer…”
Get full text

Tumour-inhibiting platinum complexes--state of the art and future perspectives by Jakupec, M A, Galanski, M, Keppler, B K

“…Thirty years after the onset of the first clinical studies with cisplatin, the development of antineoplastic platinum drugs continues to be a productive field…”
Get more information

Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance by Miklos, W, Pelivan, K, Kowol, C.R, Pirker, C, Dornetshuber-Fleiss, R, Spitzwieser, M, Englinger, B, van Schoonhoven, S, Cichna-Markl, M, Koellensperger, G, Keppler, B.K, Berger, W, Heffeter, P

“…Highlights • New triapine-resistant cell line was generated by drug selection. • Triapine-resistant cells are cross-resistant against several ABCB1 substrates…”
Get full text

Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019 by Heffeter, P, Riabtseva, A, Senkiv, Y, Kowol, C R, Körner, W, Jungwith, U, Mitina, N, Keppler, B K, Konstantinova, T, Yanchuk, I, Stoika, R, Zaichenko, A, Berger, W

“…Ruthenium anticancer drugs belong to the most promising non-platinum anticancer metal compounds in clinical evaluation. However, although the clinical results…”
Get more information

Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A) by Heffeter, P, Pongratz, M, Steiner, E, Chiba, P, Jakupec, M A, Elbling, L, Marian, B, Körner, W, Sevelda, F, Micksche, M, Keppler, B K, Berger, W

“…KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A) is a metal complex with promising anticancer activity. Since chemoresistance is…”
Get more information

A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl 4(Ind) 2] and serum proteins by Piccioli, F., Sabatini, S., Messori, L., Orioli, P., Hartinger, Ch.G., Keppler, B.K.

“…Formation of adducts between the antitumor ruthenium(III) complex [HInd] trans-[RuCl 4(Ind) 2] (KP1019) and the plasma proteins serum albumin and serum…”
Get full text

Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential by Kuhn, P-S, Pichler, V, Roller, A, Hejl, M, Jakupec, M A, Kandioller, W, Keppler, B K

“…The very promising results of Na-trans-[RuCl4(1H-indazole)2] (NKP-1339) in clinical studies have fuelled renewed interest in the research and development of…”
Get more information

HPIC-UV-ICP-SFMS study of the interaction of cisplatin with guanosine monophosphate by Hann, S, Zenker, A, Galanski, M, Bereuter, T L, Stingeder, G, Keppler, B K

“…Interaction of cis-[Pt(NH3)2Cl2] (cisplatin) with 5'-guanosine monophosphate (5'-GMP) has been investigated for the first time by on-line coupling of high…”
Get full text

Carboxylation of Dihydroxoplatinum(IV) Complexes via a New Synthetic Pathway by Galanski, M, Keppler, B. K

Get full text

Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance by Englinger, B, Mair, M, Miklos, W, Pirker, C, Mohr, T, van Schoonhoven, S, Lötsch, D, Körner, W, Ferk, F, Knasmüller, S, Heffeter, P, Keppler, B K, Grusch, M, Berger, W

“…Background: Colorectal carcinoma (CRC) is the third most common cancer worldwide. Platinum-based anticancer compounds still constitute one mainstay of systemic…”
Get full text

Preclinical activity of trans-indazolium [tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells by Depenbrock, H., Schmelcher, S., Peter, R., Keppler, B.K., Weirich, G., Block, T., Rastetter, J., Hanauske, A.-R.

“…Trans-indazolium[tetrachlorobisindazoleruthenate(III)] (KP 1019) is a new heavy metal complex with promising activity against tumour cell lines and in animal…”
Get full text

Preclinical toxicology and tissue gallium distribution of a novel antitumour gallium compound: tris (8-quinolinolato) gallium (III) by Collery, P, Domingo, J L, Keppler, B K

“…Tris (8-chinolinolato) gallium (III) compound (KP46), a new organo-metallic gallium (Ga) complex, has been synthesized for potential use in anticancer therapy…”
Get more information

Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane by SCHILLING, T, KEPPLER, K. B, HEIM, M. E, NIEBCH, G, DIETZFELBINGER, H, RASTETTER, J, HANAUSKE, A.-R

Get full text

Kinetics of binding properties of 5′-GMP with cisplatin under simulated physiological conditions by capillary electrophoresis by Zenker, Andrea, Galanski, Markus, Bereuter, Thomas L, Keppler, Bernhard K, Lindner, Wolfgang

“…Kinetics of the adduct formation of cisplatin and its hydrolysis products with 5′-GMP was investigated using capillary electrophoresis (CE) under ‘simulated…”
Get full text

Metallodrug research and analysis using capillary electrophoresis by Timerbaev, A.R., Hartinger, C.G., Keppler, B.K.

“…We review current and emerging capabilities of capillary electrophoresis (CE) as employed for metallodrug development. The application of gentle separation…”
Get full text

Pharmacological properties of cerium compounds by Jakupec, M A, Unfried, P, Keppler, B K

“…Cerium is a member of the lanthanide series or rare earth elements which exert diverse biological effects mainly by their resemblance to calcium. This…”
Get more information

Capillary electrophoretic study of cisplatin interaction with nucleoside monophosphates, di- and trinucleotides by Zenker, Andrea, Galanski, Mathea S., Bereuter, Thomas L, Keppler, Bernhard K, Lindner, Wolfgang

“…cis-Diamminedichloroplatinum(II) (cisplatin) is applied against different kinds of cancer although toxic side effects are known. Screening systems for…”
Get full text